Economic return from the women's health initiative estrogen plus progestin clinical trial: A modeling study

Joshua A. Roth, Ruth Etzioni, Teresa M. Waters, Mary Pettinger, Jacques E. Rossouw, Garnet L. Anderson, Rowan T. Chlebowski, Joann E. Manson, Mark Hlatky, Karen C. Johnson, Scott D. Ramsey

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Background: The findings of the Women's Health Initiative (WHI) estrogen plus progestin (E+P) trial led to a substantial reduction in use of combined hormone therapy (cHT) among postmenopausal women in the United States. The economic effect of this shift has not been evaluated relative to the trial's $260 million cost (2012 U.S. dollars). Objective: To estimate the economic return from the WHI E+P trial. Design: Decision model to simulate health outcomes for a "WHI scenario" with observed cHT use and a "no-WHI scenario" with cHT use extrapolated from the pretrial period. Data Sources: Primary analyses of WHI outcomes, peer-reviewed literature, and government sources. Target Population: Postmenopausal women in the United States, aged 50 to 79 years, who did not have a hysterectomy. Time Horizon: 2003 to 2012. Perspective: Payer. Intervention: Combined hormone therapy. Outcome Measures: Disease incidence, expenditure, qualityadjusted life-years, and net economic return. Results of Base-Case Analysis: The WHI scenario resulted in 4.3 million fewer cHT users, 126 000 fewer breast cancer cases, 76 000 fewer cardiovascular disease cases, 263 000 more fractures, 145 000 more quality-adjusted life-years, and expenditure savings of $35.2 billion. The corresponding net economic return of the trial was $37.1 billion ($140 per dollar invested in the trial) at a willingness-to-pay level of $100 000 per quality-adjusted life-year. Results of Sensitivity Analysis: The 95% CI for the net economic return of the trial was $23.1 to $51.2 billion. Limitation: No evaluation of indirect costs or outcomes beyond 2012. Conclusion: The WHI E+P trial made high-value use of public funds with a substantial return on investment. These results can contribute to discussions about the role of public funding for large, prospective trials with high potential for public health effects. Primary Funding Source: National Heart, Lung, and Blood Institute.

Original languageEnglish (US)
Pages (from-to)594-602
Number of pages9
JournalAnnals of internal medicine
Volume160
Issue number9
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Women's Health
Progestins
Estrogens
Economics
Clinical Trials
Hormones
Quality-Adjusted Life Years
Health Expenditures
National Heart, Lung, and Blood Institute (U.S.)
Therapeutics
Costs and Cost Analysis
Health Services Needs and Demand
Information Storage and Retrieval
Financial Management
Hysterectomy
Cardiovascular Diseases
Public Health
Outcome Assessment (Health Care)
Breast Neoplasms
Incidence

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Roth, J. A., Etzioni, R., Waters, T. M., Pettinger, M., Rossouw, J. E., Anderson, G. L., ... Ramsey, S. D. (2014). Economic return from the women's health initiative estrogen plus progestin clinical trial: A modeling study. Annals of internal medicine, 160(9), 594-602. https://doi.org/10.7326/M13-2348

Economic return from the women's health initiative estrogen plus progestin clinical trial : A modeling study. / Roth, Joshua A.; Etzioni, Ruth; Waters, Teresa M.; Pettinger, Mary; Rossouw, Jacques E.; Anderson, Garnet L.; Chlebowski, Rowan T.; Manson, Joann E.; Hlatky, Mark; Johnson, Karen C.; Ramsey, Scott D.

In: Annals of internal medicine, Vol. 160, No. 9, 01.01.2014, p. 594-602.

Research output: Contribution to journalArticle

Roth, JA, Etzioni, R, Waters, TM, Pettinger, M, Rossouw, JE, Anderson, GL, Chlebowski, RT, Manson, JE, Hlatky, M, Johnson, KC & Ramsey, SD 2014, 'Economic return from the women's health initiative estrogen plus progestin clinical trial: A modeling study', Annals of internal medicine, vol. 160, no. 9, pp. 594-602. https://doi.org/10.7326/M13-2348
Roth, Joshua A. ; Etzioni, Ruth ; Waters, Teresa M. ; Pettinger, Mary ; Rossouw, Jacques E. ; Anderson, Garnet L. ; Chlebowski, Rowan T. ; Manson, Joann E. ; Hlatky, Mark ; Johnson, Karen C. ; Ramsey, Scott D. / Economic return from the women's health initiative estrogen plus progestin clinical trial : A modeling study. In: Annals of internal medicine. 2014 ; Vol. 160, No. 9. pp. 594-602.
@article{2f2f88adc2e9474a896d2e6231cf4b8f,
title = "Economic return from the women's health initiative estrogen plus progestin clinical trial: A modeling study",
abstract = "Background: The findings of the Women's Health Initiative (WHI) estrogen plus progestin (E+P) trial led to a substantial reduction in use of combined hormone therapy (cHT) among postmenopausal women in the United States. The economic effect of this shift has not been evaluated relative to the trial's $260 million cost (2012 U.S. dollars). Objective: To estimate the economic return from the WHI E+P trial. Design: Decision model to simulate health outcomes for a {"}WHI scenario{"} with observed cHT use and a {"}no-WHI scenario{"} with cHT use extrapolated from the pretrial period. Data Sources: Primary analyses of WHI outcomes, peer-reviewed literature, and government sources. Target Population: Postmenopausal women in the United States, aged 50 to 79 years, who did not have a hysterectomy. Time Horizon: 2003 to 2012. Perspective: Payer. Intervention: Combined hormone therapy. Outcome Measures: Disease incidence, expenditure, qualityadjusted life-years, and net economic return. Results of Base-Case Analysis: The WHI scenario resulted in 4.3 million fewer cHT users, 126 000 fewer breast cancer cases, 76 000 fewer cardiovascular disease cases, 263 000 more fractures, 145 000 more quality-adjusted life-years, and expenditure savings of $35.2 billion. The corresponding net economic return of the trial was $37.1 billion ($140 per dollar invested in the trial) at a willingness-to-pay level of $100 000 per quality-adjusted life-year. Results of Sensitivity Analysis: The 95{\%} CI for the net economic return of the trial was $23.1 to $51.2 billion. Limitation: No evaluation of indirect costs or outcomes beyond 2012. Conclusion: The WHI E+P trial made high-value use of public funds with a substantial return on investment. These results can contribute to discussions about the role of public funding for large, prospective trials with high potential for public health effects. Primary Funding Source: National Heart, Lung, and Blood Institute.",
author = "Roth, {Joshua A.} and Ruth Etzioni and Waters, {Teresa M.} and Mary Pettinger and Rossouw, {Jacques E.} and Anderson, {Garnet L.} and Chlebowski, {Rowan T.} and Manson, {Joann E.} and Mark Hlatky and Johnson, {Karen C.} and Ramsey, {Scott D.}",
year = "2014",
month = "1",
day = "1",
doi = "10.7326/M13-2348",
language = "English (US)",
volume = "160",
pages = "594--602",
journal = "Annals of Internal Medicine",
issn = "0003-4819",
publisher = "American College of Physicians",
number = "9",

}

TY - JOUR

T1 - Economic return from the women's health initiative estrogen plus progestin clinical trial

T2 - A modeling study

AU - Roth, Joshua A.

AU - Etzioni, Ruth

AU - Waters, Teresa M.

AU - Pettinger, Mary

AU - Rossouw, Jacques E.

AU - Anderson, Garnet L.

AU - Chlebowski, Rowan T.

AU - Manson, Joann E.

AU - Hlatky, Mark

AU - Johnson, Karen C.

AU - Ramsey, Scott D.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: The findings of the Women's Health Initiative (WHI) estrogen plus progestin (E+P) trial led to a substantial reduction in use of combined hormone therapy (cHT) among postmenopausal women in the United States. The economic effect of this shift has not been evaluated relative to the trial's $260 million cost (2012 U.S. dollars). Objective: To estimate the economic return from the WHI E+P trial. Design: Decision model to simulate health outcomes for a "WHI scenario" with observed cHT use and a "no-WHI scenario" with cHT use extrapolated from the pretrial period. Data Sources: Primary analyses of WHI outcomes, peer-reviewed literature, and government sources. Target Population: Postmenopausal women in the United States, aged 50 to 79 years, who did not have a hysterectomy. Time Horizon: 2003 to 2012. Perspective: Payer. Intervention: Combined hormone therapy. Outcome Measures: Disease incidence, expenditure, qualityadjusted life-years, and net economic return. Results of Base-Case Analysis: The WHI scenario resulted in 4.3 million fewer cHT users, 126 000 fewer breast cancer cases, 76 000 fewer cardiovascular disease cases, 263 000 more fractures, 145 000 more quality-adjusted life-years, and expenditure savings of $35.2 billion. The corresponding net economic return of the trial was $37.1 billion ($140 per dollar invested in the trial) at a willingness-to-pay level of $100 000 per quality-adjusted life-year. Results of Sensitivity Analysis: The 95% CI for the net economic return of the trial was $23.1 to $51.2 billion. Limitation: No evaluation of indirect costs or outcomes beyond 2012. Conclusion: The WHI E+P trial made high-value use of public funds with a substantial return on investment. These results can contribute to discussions about the role of public funding for large, prospective trials with high potential for public health effects. Primary Funding Source: National Heart, Lung, and Blood Institute.

AB - Background: The findings of the Women's Health Initiative (WHI) estrogen plus progestin (E+P) trial led to a substantial reduction in use of combined hormone therapy (cHT) among postmenopausal women in the United States. The economic effect of this shift has not been evaluated relative to the trial's $260 million cost (2012 U.S. dollars). Objective: To estimate the economic return from the WHI E+P trial. Design: Decision model to simulate health outcomes for a "WHI scenario" with observed cHT use and a "no-WHI scenario" with cHT use extrapolated from the pretrial period. Data Sources: Primary analyses of WHI outcomes, peer-reviewed literature, and government sources. Target Population: Postmenopausal women in the United States, aged 50 to 79 years, who did not have a hysterectomy. Time Horizon: 2003 to 2012. Perspective: Payer. Intervention: Combined hormone therapy. Outcome Measures: Disease incidence, expenditure, qualityadjusted life-years, and net economic return. Results of Base-Case Analysis: The WHI scenario resulted in 4.3 million fewer cHT users, 126 000 fewer breast cancer cases, 76 000 fewer cardiovascular disease cases, 263 000 more fractures, 145 000 more quality-adjusted life-years, and expenditure savings of $35.2 billion. The corresponding net economic return of the trial was $37.1 billion ($140 per dollar invested in the trial) at a willingness-to-pay level of $100 000 per quality-adjusted life-year. Results of Sensitivity Analysis: The 95% CI for the net economic return of the trial was $23.1 to $51.2 billion. Limitation: No evaluation of indirect costs or outcomes beyond 2012. Conclusion: The WHI E+P trial made high-value use of public funds with a substantial return on investment. These results can contribute to discussions about the role of public funding for large, prospective trials with high potential for public health effects. Primary Funding Source: National Heart, Lung, and Blood Institute.

UR - http://www.scopus.com/inward/record.url?scp=84900455772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900455772&partnerID=8YFLogxK

U2 - 10.7326/M13-2348

DO - 10.7326/M13-2348

M3 - Article

C2 - 24798522

AN - SCOPUS:84900455772

VL - 160

SP - 594

EP - 602

JO - Annals of Internal Medicine

JF - Annals of Internal Medicine

SN - 0003-4819

IS - 9

ER -